News

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Why Summit Therapeutics Stock Soared 8% Higher Today
A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...
Forbes India5d
Maky Zangenah: Taking cancer drug maker Summit Therapeutics to staggering heights
Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...
2 Soaring Stocks With More Upside Potential to Buy and Hold
Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...
The AM Reporter2d
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from HC Wainwright
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued ...
Zacks Investment Research on MSN2d
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
Shares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...
MarketWatch4d
Revolution Medicines, Summit Therapeutics Partner to Evaluate Combination of Treatments in Certain Cancers
Revolution Medicines and Summit Therapeutics entered into a clinical collaboration in multiple solid-tumor settings to evaluate their respective treatments in combination with each other. Redwood ...
Lineage Cell Therapeutics unveils promising Phase I/IIa OpRegen results at CTS 2025
OpRegen is a suspension of embryonic stem cell-derived RPE cells restoring visual function in degenerative retinal ...